Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Projection: Expected to Surpass $82.61 Billion by 2030 at 15.8% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market from 2026–2035 with trusted insights from The Business Research Company
What growth pattern is forecast for the Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market size between 2026 and 2035?
The market size for messenger ribonucleic acid (mrna) and next-generation vaccine platforms has experienced swift expansion recently. This market is projected to expand from $39.69 billion in 2025 to $45.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.6%. Key factors contributing to its historical growth include covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is anticipated to undergo significant expansion in the coming years. Its valuation is projected to reach $82.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period can be attributed to factors such as the rise of personalized cancer vaccines, the broadening of infectious disease pipelines, swifter platform-based approvals, increased funding in biotechnology, and the more extensive application of therapeutic vaccines. Prominent trends for the forecast period include self-amplifying mRNA platforms, advancements in lipid nanoparticle delivery, the adoption of modular vaccine platform designs, quick adaptation to pathogen targets, and the emergence of next-generation adjuvant systems.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp
Which Drivers Are Impacting Market Performance In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
The escalating need for personalized medicine is anticipated to propel the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market going forward. Personalized medicine, a medical approach, involves customizing disease prevention and treatment strategies based on an individual’s genetic profile, molecular characteristics, and specific health conditions. The heightened demand for personalized medicine stems from the rising prevalence of complex and chronic diseases, as these conditions necessitate targeted and patient-specific therapeutic solutions to enhance treatment efficacy and safety outcomes. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms aid personalized medicine by enabling rapid, flexible, and highly specific vaccine and therapeutic designs that can be tailored to individual genetic and disease profiles, thereby supporting precision-based healthcare delivery. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, 16 new personalized treatments for rare disease patients received FDA approval in 2023, an increase from six in 2022. Therefore, the escalating demand for personalized medicine is driving the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.
What Segment Types Are Examined In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –
1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types
2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies
3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications
4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics
Subsegments:
1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines
2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines
3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines
4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines
5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines
6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines
Which Trends Are Guiding The Evolution Of The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
Major companies in the mRNA and next-generation vaccine platforms market are prioritizing the development of advanced mRNA-based COVID-19 vaccines to enhance immune endurance, broaden variant coverage, and improve overall vaccine performance. These next-generation mRNA COVID-19 vaccines leverage refined mRNA engineering and delivery technologies to provide more extensive and lasting protection against existing and emerging SARS-CoV-2 variants, while also boosting safety, stability, and storage convenience, and allowing for rapid adaptation to viral evolution. For instance, in June 2025, Moderna Inc., a US-based biotechnology company, launched mNEXSPIKE, its next-generation COVID-19 vaccine designed to strengthen protection against circulating and emerging SARS-CoV-2 variants. This vaccine features an updated spike protein antigen that more accurately matches recent variants, aiming to deliver enhanced immune durability and effectiveness to support ongoing COVID-19 prevention efforts and future booster strategies.
Who Are The Major Companies Operating In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33215&type=smp
Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company
Mrna Cancer Vaccines And Therapeutics Market Report 2026
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
